Goldman Sachs Maintains Neutral on GoodRx Holdings, Lowers Price Target to $2.5
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4 to $2.5.
Goldman Sachs analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4 to $2.5.